News

WHO Issues Alert on Falsified Diabetes and Obesity Medicines

Amazon Store

The World Health Organization (WHO) has issued a medical product alert regarding falsified semaglutides, a type of medicine used to treat type 2 diabetes and obesity in some countries. Three falsified batches of the product, specifically the brand Ozempic, have been detected in Brazil, the UK, and the US. WHO has observed an increase in reports of falsified semaglutide products globally since 2022.

The falsified medicines can have harmful effects on health, including unmanaged blood glucose levels or weight, and may contain undeclared ingredients that can lead to unpredictable health risks. WHO advises healthcare professionals, regulatory authorities, and the public to be aware of these falsified batches and to report any suspicious medicines to relevant authorities.

Patients can protect themselves by buying medicines with prescriptions from licensed physicians, checking packaging and expiry dates, and using products as prescribed. WHO is working on a rapid advice guideline on the use of semaglutides for obesity treatment and encourages notifications on falsified medicines to be sent to rapidalert@who.int.

WHO/Ruth Abla ADJORLOLO